Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable (II)-67-1 pseudogene is a member of the immunoglobulin heavy chain variable (IGHV) gene locus. Immunoglobulin heavy chain variable genes encode the variable region of the heavy chains in immunoglobulins (antibodies), which are critical for antigen binding and the adaptive immune response[2][4]. However, the "67-1" variant with the (II) subfamily or family designation, is only listed in certain commercial or reference databases as a **pseudogene**, meaning it does not generate a functional heavy chain protein due to mutations or loss of coding potential[1].\nIGHV pseudogenes, including IGHV(II)-67-1, are not involved in antigen binding, immune signaling, or considered therapeutic targets. Therefore, this entity is **not used in drug discovery, is not linked to any disease as a biomarker, nor targeted by any approved or investigational therapies**. Instead, it serves a genomic/phylogenetic reference in studies of antibody gene evolution and diversity[4].\n\n**Critical note:** This gene segment is not a functional receptor, protein, or verified entity in the context of pharmacological targeting; literature and reference databases do not list it as such[1][4]. It is classified as a **pseudogene** and does not encode a functional immunoglobulin domain.\n\n**Additional context:**\n- The functional immunoglobulin heavy variable genes (e.g., IGHV6-1, IGHV1-24) are essential for immune function, encode antigen-binding sites, and are targeted during therapeutic antibody generation[3][5]. However, pseudogenes like IGHV(II)-67-1 lack such utility or disease association.\n- If you require information on a functional IGHV gene relevant to therapeutic antibodies, you may refer to IGHV1-69, IGHV3-23, or others, but not IGHV(II)-67-1[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable (II)-67-1 pseudogene (IGHV(II)-67-1).